NCT06867562 - Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Platinum-Resistant Primary Peritoneal CarcinomaPlatinum Resistant High Grade Epithelial Ovarian CancerPlatinum Resistant High Grade Serous Ovarian Cancer

Interventions

DRUG

Paclitaxel Lipid Suspension

The formulation consists of uniformly sized (\< 100 nm) particles of Paclitaxel suspended in a lipid-based formulation. The advantage of such a Lipid-Based formulation of Paclitaxel is an improvement of the safety profile by eliminating excipients, Cremophor and ethanol which are present in conventional Paclitaxel formulations (Taxol®).

DRUG

Conventional paclitaxel or Taxol

Conventional formulation with detergent Cremophor and alcohol